Company / SG&A Expense
Neurogene Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$22.6M
FY2025
5-year range
$9.3M / $22.6M
FY2021-FY2025
Trend
+102.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $15M to $23M over the past 6 years.
Based on SEC 10-K filings.
$23M in FY2025.
Increased from $15M to $23M over the past 6 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a expense increased 102.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.6M | +102.1% |
| FY2024 | $11.2M | -24.7% |
| FY2019 | $14.9M | +60.3% |
| FY2018 | $9.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026